1. Home
  2. UTF vs SRPT Comparison

UTF vs SRPT Comparison

Compare UTF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$27.68

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$18.89

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
SRPT
Founded
N/A
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
UTF
SRPT
Price
$27.68
$18.89
Analyst Decision
Hold
Analyst Count
0
29
Target Price
N/A
$25.85
AVG Volume (30 Days)
285.7K
3.6M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.88
Revenue
N/A
$2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.13
Revenue Growth
N/A
15.58
52 Week Low
$23.42
$10.42
52 Week High
$27.90
$25.32

Technical Indicators

Market Signals
Indicator
UTF
SRPT
Relative Strength Index (RSI) 59.61 56.25
Support Level $26.54 $15.55
Resistance Level $27.90 $19.70
Average True Range (ATR) 0.31 1.05
MACD 0.01 0.37
Stochastic Oscillator 81.00 62.87

Price Performance

Historical Comparison
UTF
SRPT

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: